NSC 119915Z | 500533-96-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: NSC 119915Z
• 英文别名: NSC119915；3-(4,5,6-trihydroxy-3-oxo-xanthen-9-yl)propanoic acid；3-(3,4,5-Trihydroxy-6-oxoxanthen-9-yl)propanoic acid
• CAS: 500533-96-0
• 化学式: C₁₆H₁₂O₇
• 分子量: 316.267
• InChiKey: OCMFSQMNSIPSJS-UHFFFAOYSA-N

物化性质

• 沸点：
  694.6±55.0 °C(Predicted)
• 密度：
  1.71±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  124
• 氢给体数：
  4
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  NSC 119915Z 、 C₅₇H₁₀₄N₈O₃₁ 在 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 3,3’-((2-(14-(((3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-5-oxo-2,9,12-trioxa-6-azatetradecyl)-2-(2-(3-(4,5,6-trihydroxy-3-oxo-3H-xanthen-9-yl)propanamido)acetamido)propane-1,3-diyl)bis(oxy))bis(N-(2-(2-(2-(((2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)ethoxy)ethoxy)ethyl)propanamide)
  参考文献：
  名称：

  [EN] TARGETED BIFUNCTIONAL DEGRADERS
  [FR] AGENTS DE DÉGRADATION BIFONCTIONNELS CIBLÉS

  摘要：

  本发明在一个方面提供了可以用来促进或增强降解某些循环蛋白的双功能化合物。在另一个方面，本发明提供了可以用来促进或增强降解某些自身抗体的双功能化合物。在某些实施方式中，治疗或管理疾病和/或疾病需要降解、去除或减少受试者体内循环蛋白或自身抗体的浓度。因此，在某些实施方式中，将本发明的化合物给予受试者可去除或减少循环蛋白或自身抗体的循环浓度，从而治疗、改善或预防疾病和/或疾病。在某些实施方式中，循环蛋白是TNF。

  公开号：

  WO2021072269A1

文献信息

• [EN] BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS<br/>[FR] PETITES MOLÉCULES BIFONCTIONNELLES POUR CIBLER LA DÉGRADATION SÉLECTIVE DE PROTÉINES CIRCULANTES
  申请人：UNIV YALE

  公开号：WO2019199634A4

  公开（公告）日：2019-12-05
• VANADYL AND VANADATE FOR USE IN REDUCING STRESS -INDUCED METABOLIC DERANGEMENT
  申请人：CFM Pharma Holding BV

  公开号：EP3684352A1

  公开（公告）日：2020-07-29
• Methods of Inhibiting Poxvirus Growth
  申请人：Sefton Bartholomew M.

  公开号：US20080306031A1

  公开（公告）日：2008-12-11

  This disclosure ascribes new functions to derivatives of tetralin, anthraquinone, naphthylamine, tri-amino-pyrimidine, xanthen-3-one, and/or cinnamic acid (including, for example, NSC270718R, NSC117285R, NSC170008Y, NSC306711P, NSC119913X, NSC119915Z, NSC119911V, NSC119910U, NSC128437O, NSC125908P, NSC9600Q, or NSC13778J, each obtained from the Structure Diversity Set, National Institutes of Health, National Cancer Institute, Developmental Therapeutics Program). These compounds are shown to be effective inhibitors of viral essential protein kinases (such as poxvirus B1 and/or F10 protein kinases). Exemplary chemical structures for viral protein kinase (VPK) inhibitors are provided, as are methods of using such compounds, for instance, to inhibit VPK activity and/or poxvirus growth, and/or for the treatment of poxvirus infection. Also provided are pharmaceutical compositions including disclosed VPK inhibitors.
• METHODS AND COMPOUNDS FOR REGULATING APOPTOSIS
  申请人：Reed John C.

  公开号：US20090118135A1

  公开（公告）日：2009-05-07

  An assay for determining compounds that inhibit activity of a BCl-2 protein, or affect conversion of Bcl-2 from an antiapoptotic to a proapoptotic form are described. In addition, compounds that modulate the function of anti-apoptotic proteins such as Bcl-2 and related Bcl-2 family members are identified.
• COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING
  申请人：Smrcka Alan V.

  公开号：US20090221691A1

  公开（公告）日：2009-09-03

  The present invention relates to methods for identifying agents which bind to specific amino acid residues of the protein interaction site of G protein β protein subunit. Compounds identified in accordance with the assay of the invention and methods for using the compound for modulating at least one activity of a G protein are also provide.